Integral Diagnostics Ltd. (IDX) AI Stock Analysis

Integral Diagnostics Ltd. has disclosed a change in director Kevin Shaw’s interest in the company’s securities, reflecting an on-market acquisition of additional ordinary shares via an indirect holding structure. Following the transaction...

Integral Diagnostics has reported that all resolutions put to shareholders at its 29 October 2026 annual general meeting were passed by comfortable majorities. Investors endorsed the remuneration report, director re-elections, new and pro‑rata...

Integral Diagnostics reported strong FY26 growth, with revenue rising 25.6% to $788.7 million and operating EBITDA up 30.3% to $164.8 million, lifting its operating margin to 20.9% and operating NPAT to $47.4 million. Statutory NPAT surged over 600%...

Integral Diagnostics has disclosed a change in the shareholding of director James Tobias Hall, following the issue of additional ordinary shares under the company’s Dividend Reinvestment Plan. Hall’s total holding increased from 276,571 t...

Integral Diagnostics Limited has notified the market of the issue of 224,799 unquoted performance rights under its short‑term incentive (STI) employee scheme, effective 30 September 2026. These securities, identified under ASX code IDXAF, are s...

Integral Diagnostics has scheduled its 2026 Annual General Meeting for 29 October 2026 at 10:00am Melbourne time, offering shareholders the option to attend in person in Melbourne or participate online via the Computershare Meeting Platform. The comp...

Integral Diagnostics Ltd., a provider of diagnostic imaging services listed on the ASX under ticker IDX, operates across Australia delivering radiology and related imaging solutions. The company’s ordinary fully paid shares form the basis for i...

Wilson Asset Management Group has lodged a notice indicating it has ceased to be a substantial holder in Integral Diagnostics, effective 5 May 2026. The filing, made under section 671B of the Corporations Act, reflects changes in Wilson Asset Managem...

Integral Diagnostics Ltd has disclosed a change in its issued capital following the lapse of 144,754 Short-Term Incentive performance rights. The rights ceased on 27 August 2026 after the conditions attached to them were not met or became incapable o...

Integral Diagnostics Ltd. has announced that 680,124 performance rights under its long-term incentive plan have lapsed after the specified conditions were not met, resulting in a reduction in potential equity-based remuneration. The cessation of thes...

Integral Diagnostics Ltd. is an Australian-listed healthcare company operating in diagnostic imaging services, with its ordinary fully paid shares traded on the ASX under the ticker IDX. The company participates in the broader medical diagnostics sec...

Integral Diagnostics has disclosed a change in the shareholding of director Ingrid Anne Player, who increased her indirect interest in the company. The shares are held through Pisi Pty Ltd as trustee of The Huybers Family Account, reflecting a higher...

Integral Diagnostics Limited has disclosed a change in director Jason Martinez’s holdings, with the director acquiring 30,000 fully paid ordinary shares in the company. The shares were purchased on market at a price of $2.39 per share, marking...

Integral Diagnostics reported strong full-year 2026 results, with revenue rising 25.6% to $788.7 million and operating EBITDA up 30.3% to $164.8 million, lifting the margin to 20.9%. Operating NPAT surged 50.1% to $47.4 million and operating diluted...

Integral Diagnostics Ltd. has released its 2026 Annual Report for the year ended 30 June 2026, highlighting its commitment to placing patients at the centre of its radiology and diagnostic operations. The report reinforces a corporate culture built a...

Integral Diagnostics Limited, listed on the ASX as IDX, operates a network of medical imaging services across Australia and New Zealand, staffed by leading radiologists and diagnostic imaging specialists. The group’s medical leadership model ai...

Integral Diagnostics reported preliminary unaudited FY26 results showing strong growth, with revenue rising about 25% to roughly $788–$790 million and operating EBITDA up around 30%, supported by a full-year contribution from Capitol Health. Th...

Integral Diagnostics Limited has appointed Jason Martinez as a director effective 6 August 2026, according to a filing with the ASX. The company reported that Martinez currently holds no relevant interests in the company’s securities, either di...